The Power of 360°
Advanced Wound Care, Within Reach

360° Advanced Wound Care transforms the continuum of care by providing science, product solutions and service to fully meet the needs of your patients and practice.
Transforming Wound Care Today

360° Advanced Wound Care is focused on research and innovation for the management of burns, and acute and chronic wounds. Our commitment is to provide a comprehensive suite of evidence-based product solutions coupled with industry leading science and service initiatives to support both the patients’ natural restorative healing process and the providers’ goals of healing complex wounds efficiently and effectively at every stage of the wound healing process.
360° Comprehensive Continuum of Care

Our comprehensive suite of product and service solutions offer a holistic approach to patient care by supporting the wound healing process throughout the continuum of care.

Industry-leading Product Solutions

Backed by science and clinical data, 360° Advanced Wound Care offers you the right product at the right time for the right clinical need.

SUPPORTIVE DRESSINGS

Following practical wound care guidelines, Integra products are designed to support the healing process of burns, acute and chronic wounds at every stage of the wound healing process.

PREPARE

TREAT

PROTECT

PREPARE

MEDIHONEY®
Wound and Burn Dressing
Versatile and effective wound bed preparation

MEDIHONEY®
Wound and Burn Dressing
Versatile and effective wound bed preparation

TREAT

AmnioMatrix®
Amniotic Allograft Suspension
Cryopreserved suspension allograft derived from the amniotic membrane and components of the amniotic fluid

AmnioMatrix®
Amniotic Allograft Membrane
Providing key components found in the human amnion to repair, reconstruct, and replace wound tissue

Omnigraft®
Dermal Regeneration Matrix
The ONLY FDA-approved product to regenerate native dermal tissue for the treatment of DFUs

PriMatrix/PriMatrix® Ag
Dermal Repair Scaffold
Novel acellular dermal repair scaffold that supports cellular repopulation and revascularization

PROTECT

SUPPORTIVE DRESSINGS

Xtrasorb®
Wound Dressing
Novel portfolio of dressings that maximizes absorption and fluid handling

Bioguard®
Barrier Dressing
Barrier protection against a broad spectrum of pathogens including MRSA

Algicell® Ag
Wound Dressing
Providing the power, performance and protection of silver for your wound management needs
Care Plan Team Services and Support

Integra® is the premier treatment partner for wound care clinics, offering comprehensive customer and clinical support designed to optimize wound care management and limit uncertainty.

YOUR CARE TEAM
- Dedicated sales specialists
- Partners with you as part of your Care Plan Team
- Professional and timely interaction to enhance patient care

REIMBURSEMENT
- Reimbursement Hotline to help answer coding and coverage questions about Integra products
- Billing and documentation support services for Integra products
- Reimbursement educational programs

SUPPORT
- Product ordering and invoicing services
- Expedites product shipments to ensure adequate supply
- Product information support services

MEDICAL EDUCATION
- Continuing education workshops and online courses
- CME and CE educational support
- Clinical support team for product knowledge and usage

Integra® Reimbursement Hotline Services

PHONE: 1-877-444-1122, option 3
FAX: 1-888-807-0571
EMAIL: smartreimbursement@integralife.com
WEB: Integralife.com

For assistance with the following:
- Insurance benefits verification
- Prior authorizations
- Predeterminations
- Claims review
- Navigating the approval process

Disclaimer: Integra intends to use reasonable efforts to provide insurance coding advice, but this advice should not be construed as providing clinical advice, dictating reimbursement policy or substituting for the judgment of a practitioner. It is always the provider’s responsibility to determine and submit appropriate codes, charges, and modifiers for services that are rendered. Provider is responsible for verifying coverage with the patient’s insurance carrier. Integra LifeSciences Corporation assumes no responsibility for the timeliness, accuracy and completeness of the information contained herein. Since reimbursement laws, regulations, and policies change frequently, it is recommended that providers consult with their payers, coding specialists and/or legal counsel regarding coverage, coding, and payment issues.

Your Outcomes Partner

Integra is your partner in patient outcomes by offering 360° advanced wound care at every level

1. Integra Advantage Program to support business and evidence-based practice optimization
2. Comprehensive end-to-end portfolio of innovative, evidence-based solutions
3. Coding & Documentation educational programs
4. Clinical outcomes support
The Power of 360° Advanced Wound Care, Within Reach

360° Advanced Wound Care is transforming the continuum of care by:

• Offering science, product solutions and service to fully meet your patients’ needs
• Advancing wound care through industry-leading research and development
• Providing comprehensive, evidence-based, wound care solutions

Omnigraft® Dermal Regeneration Matrix

Indications: Omnigraft is indicated for use in the treatment of partial and full-thickness neuropathic diabetic foot ulcers that are greater than six weeks in duration, with no capsule, tendon or bone exposed, when used in conjunction with standard diabetic ulcer care. Contraindications: Omnigraft should not be used in patients with known sensitivity to bovine or chondroitin materials. Omnigraft should not be used on clinically diagnosed infected wounds. Warnings: Debridement or excision must be done thoroughly to remove any remaining necrotic tissue that may delay healing or cause infection. Omnigraft will not incorporate into a wound bed of nonviable tissue. Leaving any remaining nonviable tissue may create an environment for bacterial growth. Precautions: The following complications are possible with the use of wound treatments. The product should be removed if any of these conditions occur: infection, chronic inflammation (initial application of wound products may be associated with transient, mild, localized inflammation), allergic reaction, excessive redness, pain, or swelling. There have been no clinical studies evaluating Omnigraft in pregnant women. Caution should be exercised before using Omnigraft in pregnant women. Such use should occur only when the anticipated benefit clearly outweighs the risk. Adverse Events: All adverse events that were reported in the study evaluating Omnigraft for the treatment of diabetic foot ulcers at a frequency of ≥ 1% in either cohort are presented in Table 1 in the Instructions for Use. This table includes adverse events that were both attributed to and not attributed to treatment. The most common adverse events experienced by patients treated with Omnigraft were: wound infection (15%), new, worsening, or recurring wounds (14%), pain around the wound (9%), infection beyond the wound (either cellulitis or osteomyelitis, 14%); swelling (5%); nausea (5%); worsening health condition (4%). These adverse events occurred in a similar or lower percentage of patients treated with Omnigraft compared to patients treated with standard wound care alone. Omnigraft is also marketed as Integra Dermal Regeneration Template and has been studied extensively in life-threatening thermal injuries and scar contracture reconstruction. Refer to the Integra® Dermal Regeneration Template package insert for complete adverse event information.


For more information or to place an order, please contact: United States, Canada, Asia, Pacific, Latin America
USA 800-654-2873 888-980-7742 fax International +1 609-936-5400 +1 609-750-4259 fax integralife.com/contact

AmnioExcel, AmnioMatrix, Bioguard, MediHoney, Omnigraft, PriMatrix, PriMatrix Ag, TCC-EZ, Xtrasorb, Integra, and the Integra logo are registered trademarks of Integra LifeSciences Corporation or its subsidiaries in the United States and/or other countries.
©2018 Integra LifeSciences Corporation. All rights reserved. Printed in USA. 1073495-1-EN

AmnioExcel and AmnioMatrix are regulated as Human Cellular and Tissue-Based Products (HCT/P) under Section 361 of the Public Health Service Act and as such are governed by the FDA Center for Biologics Evaluation and Research (CBER).